

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously Presented) A method of reducing breast density, comprising percutaneously administering, to a patient having class III or class IV dense breast composition, a pharmaceutical composition for percutaneous administration comprising 4-hydroxy tamoxifen and isopropyl myristate.
2. (Original) A method according to claim 1, wherein said dense breast tissue is diffuse.
3. (Original) A method according to claim 1, wherein said dense breast tissue is nodular.
4. (Canceled)
5. (Previously Presented) A method according to claim 1, wherein said 4-hydroxy tamoxifen is a blend of *trans* and *cis* isomers.
6. (Original) A method according to claim 1, wherein said 4-hydroxy tamoxifen is a *trans* isomer.
7. (Original) A method according to claim 1, wherein greater than about 0.5 mg/breast of said 4-hydroxy tamoxifen is administered per day.
8. (Original) A method according to claim 1, wherein greater than about 0.75 mg/breast of said 4-hydroxy tamoxifen is administered per day.
9. (Original) A method according to claim 1, wherein greater than about 1.0 mg/breast of said 4-hydroxy tamoxifen is administered per day.

10. (Previously Presented) A method according to claim 1, wherein said pharmaceutical composition comprises a hydroalcoholic gel.
11. (Original) A method according to claim 10, wherein said hydroalcoholic gel comprises ethyl alcohol, isopropyl myristate, and hydroxypropylcellulose.
12. (Previously Presented) A method according to claim 1, wherein said pharmaceutical composition comprises an alcoholic solution.
13. (Previously Presented) A method of improving mammographic sensitivity that comprises performing the method of claim 1, then performing mammography on said patient.
14. (Canceled)
15. (Currently Amended) A method according to claim 13, wherein said 4-hydroxy tamoxifen is a ~~racemic~~ blend of *trans* and *cis* isomers.
16. (Previously Presented) A method according to claim 13, wherein said 4-hydroxy tamoxifen is a *trans* isomer.
17. (Previously Presented) A method according to claim 13, wherein greater than about 0.5 mg/breast of said 4-hydroxy tamoxifen has been administered per day.
18. (Previously Presented) A method according to claim 13, wherein greater than about 0.75 mg/breast of said 4-hydroxy tamoxifen has been administered per day.
19. (Previously Presented) A method according to claim 13, wherein greater than about 1.0 mg/breast of said 4-hydroxy tamoxifen has been administered per day.
20. (Previously Presented) A method according to claim 13, wherein said pharmaceutical composition comprises a hydroalcoholic gel.
21. (Previously Presented) A method according to claim 20, wherein said hydroalcoholic gel comprises ethyl alcohol, isopropyl myristate, and hydroxypropylcellulose.
22. (Canceled)

23. (Previously Presented) A method according to claim 10, wherein said pharmaceutical composition comprises 4-hydroxy tamoxifen, ethyl alcohol, isopropyl myristate, hydroxypropylcellulose and phosphate buffer.

24. (Previously Presented) A method according to claim 10, wherein said pharmaceutical composition comprises from about 0.001 g to about 1.0 g of 4-hydroxy tamoxifen per 100 g gel.

25. (Previously Presented) A method according to claim 24, wherein said pharmaceutical composition comprises from about 0.01 g to about 0.1 g of 4-hydroxy tamoxifen per 100 g gel.

26. (Previously Presented) A method according to claim 20, wherein said pharmaceutical composition comprises 4-hydroxy tamoxifen, ethyl alcohol, isopropyl myristate, hydroxypropylcellulose and phosphate buffer.

27. (Previously Presented) A method according to claim 20, wherein said pharmaceutical composition comprises from about 0.001 g to about 1.0 g of 4-hydroxy tamoxifen per 100 g gel.

28. (Previously Presented) A method according to claim 27, wherein said pharmaceutical composition comprises from about 0.01 g to about 0.1 g of 4-hydroxy tamoxifen per 100 g gel.